UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) March 14, 2006
Targeted
Genetics Corporation
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Washington
|
|
0-23930
|
|
91-1549568 |
|
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.) |
| |
|
|
| 1100 Olive Way, Suite 100, Seattle, Washington
|
|
98101 |
|
|
|
|
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s
telephone number, including area code (206) 623-7612
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01. Other Events.
On March 14, 2006, Targeted Genetics announced that it completed a public offering of
approximately 12.8 million shares of its common stock at a price of $0.39 per share to
institutional investors, for gross proceeds of approximately $5 million. A copy of Targeted
Genetics’ press release announcing the completion of the public offering is attached as Exhibit
99.1 to this current report and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Exhibits.
| |
99.1 |
|
Press Release of Targeted Genetics Corporation dated March 14, 2006 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| |
|
|
|
|
| |
Targeted Genetics Corporation
|
|
| |
By: |
/s/ David J. Poston
|
|
| |
|
David J. Poston |
|
| |
|
Chief Financial Officer |
|
| |
Dated: March 14, 2006